BioNTech's checkpoint inhibitor shows survival boost in advanced lung cancer
BioNTech presented new data on its CTLA-4 antibody gotistobart in previously treated lung cancer patients. The treatment extended median survival by 8.5 months compared to a control group. The results strengthen the case for the drug's continued development in this setting.
BioNTech has presented fresh clinical data for gotistobart, its CTLA-4 checkpoint inhibitor, in patients with advanced lung cancer who had already received prior treatment. The findings showed the therapy extended median survival by 8.5 months compared with the control group, a substantial improvement in a population with limited remaining options.
These results strengthen the rationale for advancing gotistobart through further development in this specific setting. The data also mark a notable step for BioNTech's oncology pipeline, suggesting its checkpoint inhibitor could complement the company's broader immunotherapy efforts beyond its better-known mRNA-based work.
These findings could offer renewed hope for patients with advanced lung cancer who have exhausted earlier treatment lines, potentially adding meaningful months of life. If the drug continues to perform well in larger trials, it may eventually give oncologists another therapeutic option in a disease where choices narrow over time. However, survival benefits must be weighed against tolerability and access, and regulatory approval remains uncertain. The ultimate societal impact will depend on whether these results translate into an affordable, widely available treatment that improves outcomes in everyday clinical practice.